Skip to content
Screener

Protagonist Therapeutics PTGX Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$7.4MMiss by $1.3M
EPS-$0.69Miss by $0.16
Revenue estimate$8.7M
EPS estimate-$0.53

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$240.1M
EPS estimate$2.43

Financials

Q4 2025

Income statement

See full
Revenue$7.4M-95.6%
Operating income-$50.4M-140%
Net income-$44.4M-134%
EPS (diluted)-$0.70-135%

Balance sheet

See full
Cash & equivalents$128.4M+32.0%
Total debt$10.3M-5.0%
Total equity$614.7M-9.0%
Total assets$668.2M-10.3%

Cash flow

See full
CapEx$144.0K-53.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$5.46B+137%
Enterprise value$5.34B+141%
P/S118.7×+113×

Profitability

See full
Operating margin-343.6%-402pp
Net margin-282.8%-346pp

Returns & leverage

See full
Return on equity-20.2%-74.6pp
Debt / equity0×0.0×
Current ratio12.7×+0.2×

FAQ

When did Protagonist Therapeutics report Q4 2025 earnings?
Protagonist Therapeutics (PTGX) reported Q4 2025 earnings on February 25, 2026 before market open.
What were Protagonist Therapeutics's Q4 2025 revenue and EPS?
Protagonist Therapeutics reported revenue of $7.4M and eps of $-0.69 for Q4 2025.
Did Protagonist Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $8.7M by $1.3M. EPS missed the consensus estimate of $-0.53 by $0.16.
How did Protagonist Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 95.6% from $170.6M a year earlier.
Where can I find Protagonist Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-019658) and the 10-K periodic report (0001104659-26-019696) directly on SEC EDGAR. The filing index links above go to sec.gov.